Onward Medical N.V.
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more
Onward Medical N.V. (ONWD) - Net Assets
Latest net assets as of June 2025: €27.72 Million EUR
Based on the latest financial reports, Onward Medical N.V. (ONWD) has net assets worth €27.72 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€56.41 Million) and total liabilities (€28.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €27.72 Million |
| % of Total Assets | 49.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 104.0 |
Onward Medical N.V. - Net Assets Trend (2017–2024)
This chart illustrates how Onward Medical N.V.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Onward Medical N.V. (2017–2024)
The table below shows the annual net assets of Onward Medical N.V. from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €48.05 Million | +167.99% |
| 2023-12-31 | €17.93 Million | -65.93% |
| 2022-12-31 | €52.63 Million | -36.35% |
| 2021-12-31 | €82.68 Million | +357.62% |
| 2020-12-31 | €-32.09 Million | -115.07% |
| 2019-12-31 | €-14.92 Million | -45.32% |
| 2018-12-31 | €-10.27 Million | -163.85% |
| 2017-12-31 | €-3.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Onward Medical N.V.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17232100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €5.36 Million | 11.14% |
| Other Comprehensive Income | €6.77 Million | 14.09% |
| Other Components | €217.77 Million | 453.19% |
| Total Equity | €48.05 Million | 100.00% |
Onward Medical N.V. Competitors by Market Cap
The table below lists competitors of Onward Medical N.V. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kginicis Co.Ltd
KQ:035600
|
$107.55 Million |
|
Nafoods Group JSC
VN:NAF
|
$107.55 Million |
|
Foresight Financial
OTCQX:FGFH
|
$107.56 Million |
|
C0X
F:C0X
|
$107.61 Million |
|
EQL PHARMA AB
F:7JK
|
$107.48 Million |
|
Reconnaissance Energy Africa Ltd
OTCQX:RECAF
|
$107.46 Million |
|
AMTD Digital Inc.
NYSE:HKD
|
$107.38 Million |
|
POLIGHT ASA NK -04
F:3OL0
|
$107.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Onward Medical N.V.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,931,000 to 48,054,000, a change of 30,123,000 (168.0%).
- Net loss of 35,725,000 reduced equity.
- Other comprehensive income increased equity by 2,282,000.
- Other factors increased equity by 63,566,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-35.73 Million | -74.34% |
| Other Comprehensive Income | €2.28 Million | +4.75% |
| Other Changes | €63.57 Million | +132.28% |
| Total Change | €- | 167.99% |
Book Value vs Market Value Analysis
This analysis compares Onward Medical N.V.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €-0.49 | €3.64 | x |
| 2019-12-31 | €-0.72 | €3.64 | x |
| 2020-12-31 | €-1.54 | €3.64 | x |
| 2021-12-31 | €2.74 | €3.64 | x |
| 2022-12-31 | €1.74 | €3.64 | x |
| 2023-12-31 | €0.59 | €3.64 | x |
| 2024-12-31 | €1.08 | €3.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Onward Medical N.V. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -46396.10%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.62x
- Recent ROE (-74.34%) is below the historical average (-54.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -2091.14% | 0.05x | 0.00x | €-8.89 Million |
| 2019 | 0.00% | -2433.75% | 0.02x | 0.00x | €-11.99 Million |
| 2020 | 0.00% | -3450.69% | 0.04x | 0.00x | €-16.80 Million |
| 2021 | -41.50% | -2814.93% | 0.01x | 1.27x | €-42.58 Million |
| 2022 | -62.27% | -1578.61% | 0.03x | 1.46x | €-38.04 Million |
| 2023 | -201.78% | -6800.94% | 0.01x | 2.43x | €-37.97 Million |
| 2024 | -74.34% | -46396.10% | 0.00x | 1.62x | €-40.53 Million |
Industry Comparison
This section compares Onward Medical N.V.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $116,565,000
- Average return on equity (ROE) among peers: -113.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Onward Medical N.V. (ONWD) | €27.72 Million | 0.00% | 1.04x | $107.49 Million |
| EUROPEAN MEDICAL SOLUTIONS (ALEMS) | $9.89 Million | -7.17% | 3.42x | $49.44K |
| BioSenic S.A. (BIOS) | $2.38 Million | -535.12% | 9.56x | $1.37 Million |
| Celyad SA (CYAD) | $26.68 Million | -61.66% | 0.65x | $5.46 Million |
| Hyloris Developmentsen Sa (HYL) | $32.14 Million | -19.73% | 0.29x | $68.74 Million |
| Oxurion NV (OXUR) | $109.86 Million | -54.90% | 0.11x | $25.86K |
| Tubize-Fin (TUB) | $518.43 Million | 0.00% | 0.25x | $4.26 Billion |